Versiani M, da Silva J A, Mundim F D
J Int Med Res. 1980;8(1):22-30. doi: 10.1177/030006058000800104.
Two double-blind trials comparing loxapine and thioridazine were conducted in hospitalized adult males diagnosed as having symptoms of chronic psychosis associated with organic brain syndrome or mental retardation. The drugs were administered orally in the ranges of loxapine 10--150 mg/day and thioridazine 150--750 mg/day for 13 weeks. In the first trial loxapine was found to be generally superior to thioridazine on the Brief Psychiatric Rating Scale, Nurses Observation Scale for In-Patient Evaluation and Clinical Global Impression. The second trial failed to confirm this superiority. The heterogeneity of diagnostic categories included may explain the discrepancy. Extra-pyramidal symptoms and sedative effects were common to both groups and consistent with the pharmacologic profiles of the study drugs.
两项比较洛沙平与硫利达嗪的双盲试验在被诊断患有与器质性脑综合征或智力迟钝相关的慢性精神病症状的住院成年男性中进行。药物口服给药，洛沙平剂量为10 - 150毫克/天，硫利达嗪剂量为150 - 750毫克/天，持续13周。在第一项试验中，在简明精神病评定量表、护士住院患者评定观察量表和临床总体印象量表上，发现洛沙平总体上优于硫利达嗪。第二项试验未能证实这种优越性。所纳入诊断类别的异质性可能解释了这种差异。两组的锥体外系症状和镇静作用均常见，且与研究药物的药理学特征相符。
